Frequently asked questions about INGREZZA and HD chorea

Find answers to HD chorea treatment questions, as well as links to organizations
that may be helpful for people and families living with HD chorea.

  • INGREZZA is an FDA-approved treatment for adults with the involuntary movements (chorea) of Huntington’s disease (HD).

    It is not known if INGREZZA is safe and effective in children.

    Do not take INGREZZA if you are allergic to valbenazine or any of the ingredients in INGREZZA.

  • Unlike other medications approved to treat HD chorea, INGREZZA selectively and specifically targets a protein called VMAT2.* VMAT2 aids in the release of dopamine.

    INGREZZA deactivates VMAT2 by attaching to structures, called receptors, that are found only on the VMAT2 protein. Other VMAT2 inhibitors also deactivate VMAT2 by attaching to its receptors—however, they also attach to receptors found in other areas besides VMAT2.*

    Current research suggests that INGREZZA reduces abnormal dopamine signaling that causes HD chorea. However, how INGREZZA works to treat HD chorea is not fully understood.

    * Based on laboratory tests. This does not imply a treatment advantage.

  • INGREZZA has been approved by the FDA for the treatment of HD chorea. Adults with mild, moderate, and severe uncontrollable body movements from HD chorea should talk to their healthcare provider about INGREZZA.

  • In a clinical study, most people began to experience improvement at 2 weeks.* Significant improvement was shown at 12 weeks vs placebo.

    * Patients had at least a 1-point reduction in TMC score at 2 weeks vs before treatment. This post-clinical study evaluation included 64 patients taking INGREZZA 40 mg, measuring HD chorea before starting treatment and at 2 weeks of treatment.

    INGREZZA was studied in a 12-week clinical trial. A total of 128 patients participated in the study. Results were based on 64 patients taking INGREZZA 40 mg, 60 mg, or 80 mg. The primary efficacy endpoint was change in TMC from the baseline to maintenance periods.

  • Ask your healthcare provider to explain how INGREZZA works, when to expect results, and to clarify the goals of your treatment, including what you should look for to know if it’s working.

  • 53% of people reported their overall HD chorea was “very much improved” or “much improved” at 12 weeks with the help of INGREZZA.*

    * Based on chorea severity scale at 12 weeks vs before treatment.

  • The most common side effects of INGREZZA in people with Huntington’s disease are sleepiness (somnolence), allergic itching, rash, and trouble getting to sleep or staying asleep.

    INGREZZA may cause serious side effects, including:

    • Depression and suicidal thoughts
    • Sudden swelling from an allergic reaction (angioedema)
    • Heart rhythm problems
    • Neuroleptic Malignant Syndrome (NMS)
    • Abnormal movements, including shaking, body stiffness, trouble moving or walking, or keeping your balance

    These are not all of the possible side effects of INGREZZA. Call your healthcare provider for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at or call 1-800-FDA-1088.

  • Taking INGREZZA is simple:

    • No complex dose adjustments
    • Always one capsule, once daily
    • Taken any time
    • With or without food
    • Can be added to most stable mental health regimens

    INGREZZA is the only HD chorea treatment with 3 effective dosing options and no required complex adjustments to get to an effective dose.

    Your healthcare provider will start you on 40 mg for 2 weeks and may increase your dosage every 2 weeks to 60 mg or 80 mg, depending on your treatment needs. The recommended dose of INGREZZA is 80 mg.

    If you take too much INGREZZA, call your poison control center at 1-800-222-1222.

  • INGREZZA is a capsule that is taken once a day with or without food. Take INGREZZA exactly as your healthcare provider tells you.

    Your healthcare provider will tell you how much INGREZZA to take and when to take it. Do not stop taking INGREZZA without talking to your healthcare provider first.

    If you take too much INGREZZA, call your poison control center at 1-800-222-1222.

  • Yes. The INBRACE® Support Program could help you save on your INGREZZA prescription.

    $0 copay program can make INGREZZA out-of-pocket costs for eligible patients less expensive than generics.*

    Additionally, if you do not have prescription coverage for INGREZZA and lack the financial resources to pay for the medicine, you may be able to receive your prescription at no cost through the INGREZZA Patient Assistance Program. Your healthcare provider can help you apply for the program or call 1-84-INGREZZA to learn more.

    * This offer is valid only for patients who have commercial (nongovernment-funded) insurance. Additional terms and conditions apply.

    This program is not contingent on a purchase of any kind. Product dispensed under this free trial program may not be submitted for reimbursement to any third-party payer. We reserve the right to modify or cancel the program at any time.

  • Call or email your healthcare provider (if it’s an option) and ask them to repeat any information you didn’t understand at your appointment or to explain it differently—they may not realize they might be using confusing, scientific terms.

    Also, consider including a family member, caregiver, or friend to join you at your next appointment. They can help you better understand and remember your healthcare provider’s advice and instructions.

    The Huntington’s Disease Society of America (HDSA) can connect patients and families to social workers who can help navigate the challenges of living with HD chorea.

  • There’s community and support for HD chorea patients and caregivers.

  • Are you or a loved one taking INGREZZA to treat HD chorea? Do you have an interest in sharing your story? If you’re a US resident and 18 years or older, please call 1-844-647-3992 to find out if you are eligible to participate in our Patient Ambassador Program. Any information you provide will be kept in accordance with our privacy policy.

    Please note that not all candidates will be selected to participate in the program.

You are now leaving

Neurocrine Biosciences, Inc. is not responsible for the content of linked third-party websites. Please be aware that the privacy policies and terms of use on these sites are different from Neurocrine Biosciences, Inc. policies.